UCB SA (UCB.BR)
| Previous Close | 173.95 |
| Open | 173.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 169.95 - 173.45 |
| 52 Week Range | 65.40 - 176.70 |
| Volume | |
| Avg. Volume | 206,452 |
| Market Cap | 32.442B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 140.16 |
| EPS (TTM) | 1.22 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 1.36 (0.78%) |
| Ex-Dividend Date | Apr 26, 2024 |
| 1y Target Est | 142.20 |
PR NewswireUCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting results from across its portfolio in generalized myasthenia gravis (gMG) at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) annual meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session taking place October 15—18, 2024 at the Savannah Convention Center in Savannah, Georgia, U.S.
BloombergBiotech UCB Mimics Obesity Drug Stocks With Skin Disease Focus
(Bloomberg) -- Amid the stock market frenzy surrounding weight-loss medicines, one Belgian biotech company is rewarding investors by focusing on a much more low-profile area of drug development: Treatments for skin disease. Most Read from BloombergUrban Heat Stress Is Another Disparity in the World’s Most Unequal NationSingapore Ends 181 Years of Horse Racing to Make Way for HomesFrom Cleveland to Chicago, NFL Teams Dream of Domed StadiumsWhat Do US Vehicle Regulators Have Against Tiny Cars?For
